By Press release submission |
Jan 28, 2020
In November, those who care for and those affected by cystic fibrosis (CF) were excited by the announcement from the Food and Drug Administration (FDA) that it had approved Trikafta, a new therapy to treat the underlying cause of the most common form of CF in people 12 and older.